AI Stock Analysis - BridgeBio Pharma (BBIO)
Analysis generated January 2, 2026.
BridgeBio Pharma, Inc. is a biotechnology company committed to discovering, creating, and optimizing transformative medicines with the aim of treating genetic diseases at the source. The company is involved in the research, development, and commercialization of novel treatments for patients with genetic diseases and genetically-driven cancers. BridgeBio leverages its robust pipeline of over 20 disease indications, spanning multiple therapeutic areas.
Stock Alerts - BridgeBio Pharma (BBIO)
 |
BridgeBio Pharma | January 20 Employee Rating is down by 7.3% over the last month. |
|
BridgeBio Pharma | January 13 Insider Alert: Kumar Neil is selling shares |
|
BridgeBio Pharma | January 5 Price is down by -6.6% in the last 24h. |
|
BridgeBio Pharma | December 17 Insider Alert: Kumar Neil is continuing selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for BridgeBio Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 61 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 18,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 10 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,364 | Sign up | Sign up | Sign up |
| X Mentions | 13 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 83 | Sign up | Sign up | Sign up |
| Linkedin Employees | 828 | Sign up | Sign up | Sign up |
About BridgeBio Pharma
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
| Price | $77.87 |
| Target Price | Sign up |
| Volume | 1,340,000 |
| Market Cap | $14.9B |
| Year Range | $32.26 - $79.91 |
| Dividend Yield | 0% |
| Analyst Rating | 88% buy |
| Industry | Biotechnology |
In the news
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 ResultsJanuary 20 - Yahoo Entertainment |
|
 |
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks TranscriptJanuary 11 - SeekingAlpha |
|
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 11 - SeekingAlpha |
|
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study - SlideshowJanuary 8 - SeekingAlpha |
|
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study TranscriptJanuary 8 - SeekingAlpha |
Skeletal Dysplasia Market Analysis Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031January 23 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 121M | 6.6M | 114M | -183M | -173M | -0.950 |
| Q2 '25 | 111M | 3.7M | 107M | -182M | -143M | -0.950 |
| Q1 '25 | 117M | 2.6M | 114M | -167M | -126M | -0.989 |
| Q4 '24 | 5.9M | 2.1M | 3.8M | -265M | -235M | -1.374 |
| Q3 '24 | 2.7M | 600,000 | 2.1M | -162M | -140M | -0.860 |
Insider Transactions View All
| Kumar Neil filed to sell 4,530,979 shares at $76.5. January 12 '26 |
| Kumar Neil filed to sell 726,580 shares at $76.7. January 12 '26 |
| Kumar Neil filed to sell 716,061 shares at $77.6. January 12 '26 |
| Kumar Neil filed to sell 4,520,302 shares at $77.5. January 12 '26 |
| Kumar Neil filed to sell 4,537,046 shares at $75.6. January 12 '26 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gilbert Cisneros |
Oct 13, 25 | Buy | $1K - $15K |
| Gilbert Cisneros |
Sep 12, 25 | Buy | $1K - $15K |
Read more about BridgeBio Pharma (BBIO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - BridgeBio Pharma
The Market Cap of BridgeBio Pharma is $14.9B.
Currently, the price of one share of BridgeBio Pharma stock is $77.87.
The BBIO stock price chart above provides a comprehensive visual representation of BridgeBio Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling BridgeBio Pharma shares. Our platform offers an up-to-date BBIO stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, BridgeBio Pharma (BBIO) does not offer dividends to its shareholders. Investors interested in BridgeBio Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of BridgeBio Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
